Five‐year comparative risk of hepatocellular carcinoma development under entecavir or tenofovir treatment‐naïve patients with chronic hepatitis B‐related compensated cirrhosis in Taiwan

医学 恩替卡韦 肝细胞癌 内科学 胃肠病学 肝硬化 危险系数 累积发病率 入射(几何) 乙型肝炎 单变量分析 置信区间 乙型肝炎病毒 队列 多元分析 免疫学 拉米夫定 病毒 物理 光学
作者
Tsung‐Hui Hu,Sherry Yueh‐Hsia Chiu,Po‐Lin Tseng,Chien‐Hung Chen,Sheng‐Nan Lu,Jing‐Houng Wang,Chao‐Hung Hung,Kwong‐Ming Kee,Ming‐Tsung Lin,Kuo‐Chin Chang,Meng‐Chih Lin,Rong‐Nan Chien
出处
期刊:Alimentary Pharmacology & Therapeutics [Wiley]
卷期号:52 (11-12): 1695-1706 被引量:19
标识
DOI:10.1111/apt.16116
摘要

BACKGROUND: Comparative long-term efficacy of entecavir (ETV) and tenofovir disoproxil fumarate (TDF) for prevention of disease progression to hepatocellular carcinoma (HCC) among high-risk patients with chronic hepatitis B (CHB)-related compensated cirrhosis is controversial. AIMS: To compare the long-term efficacy of ETV and TDF in HCC prevention in patients with CHB-related cirrhosis, and to evaluate predictive risk factors for HCC development. METHODS: From January 2008 to March 2018, 894 treatment-naïve patients with CHB-related compensated cirrhosis on ETV or TDF were enrolled based on the longitudinal cohort study. Data were originally collected for 7.3 years of follow-up or after the launch of TDF in 2011. Only the 5-year cumulative incidence and risk factors of HCC were assessed. RESULT: Total 678 and 216 patients received ETV and TDF, respectively. The cumulative risk of HCC at 1, 3 and 5 years of follow-up was 1.6%, 11.3% and 18.7%, respectively, in the ETV group; and 0.9%, 6.7% and 10.7%, respectively, in the TDF group (P = 0.0305). Univariate and adjusted-multivariable models revealed that platelet count, alpha-fetoprotein (AFP) levels and upper gastrointestinal (UGI) varices were independent risk factors for HCC development. TDF resulted in risk of HCC development compared to ETV with adjusted hazard ratios (aHRs) of 0.66 (95% confidence interval [CI]:0.40, 1.08; P = 0.0971), 0.69 (95% CI: 0.42, 1.14; P = 0.1488) and 0.66 (95% CI: 0.38, 1.14; P = 0.1407) under stepwise selection, propensity score adjustment, and propensity score matching multivariable models, respectively. CONCLUSIONS: For treatment-naïve patients with CHB-related compensated cirrhosis with 5-year follow-up, after variable adjustments, propensity score approaches and subgroup analyses, TDF showed a lower rate of HCC development that did not reach statistical significance, compared to the ETV.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
研友_VZG7GZ应助勤奋的鸿涛采纳,获得10
1秒前
1秒前
慕青应助默默采纳,获得10
2秒前
2秒前
2秒前
3秒前
123发布了新的文献求助10
3秒前
bz完成签到,获得积分20
3秒前
CHENISTRY完成签到,获得积分10
3秒前
远不止这些完成签到,获得积分10
4秒前
4秒前
在水一方应助神勇千兰采纳,获得10
4秒前
寻悦发布了新的文献求助10
4秒前
5秒前
葡萄糖发布了新的文献求助10
5秒前
甜甜的鸿煊完成签到,获得积分20
5秒前
恢复出厂设置完成签到,获得积分10
6秒前
7秒前
7秒前
长情诺言发布了新的文献求助10
8秒前
8秒前
小马发布了新的文献求助30
8秒前
TakIc发布了新的文献求助10
9秒前
10秒前
宋嘉新发布了新的文献求助10
10秒前
10秒前
爆米花应助fgjkl采纳,获得10
10秒前
科研通AI6.4应助Ttttsyu采纳,获得10
11秒前
张zhang发布了新的文献求助10
11秒前
彭于晏应助大狒狒采纳,获得10
11秒前
12秒前
赘婿应助ttgx采纳,获得10
12秒前
fengkaobiguohei完成签到 ,获得积分10
13秒前
molihuakai应助迷路剑通采纳,获得10
13秒前
13秒前
张子豪完成签到,获得积分10
13秒前
加油小白菜完成签到,获得积分10
14秒前
14秒前
15秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
2026年中国辛酸癸酸聚乙二醇甘油酯行业市场规模及竞争格局分析报告 1000
48V Low-voltage Power Distribution Network (PDN) Architecture Industry Report, 2024 800
Fundamentals of Pharmaceutical and Biologics Regulations: A Global Perspective, Second Edition 700
Matrix Methods in Data Mining and Pattern Recognition Second Edition 510
适配Micro-LED色转换的高兼容性量子点负性光刻胶制备与工艺研究 500
Vander's Renal Physiology第10版 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 化学工程 生物化学 计算机科学 内科学 物理 复合材料 催化作用 细胞生物学 无机化学 光电子学 物理化学 电极 基因
热门帖子
关注 科研通微信公众号,转发送积分 7314987
求助须知:如何正确求助?哪些是违规求助? 8931207
关于积分的说明 18930819
捐赠科研通 6975173
什么是DOI,文献DOI怎么找? 3213771
关于科研通互助平台的介绍 2381799
邀请新用户注册赠送积分活动 2192189